Jennison Associates’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Jennison Associates’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,720,838	Closed	-$8.91M	–	832
2016 Q4	$8.91M	Buy	1,720,838 +4,988	+0.3%	+$26.2K	0.01%	485
2016 Q3	$9.56M	Sell	1,715,850 -39,185	-2%	-$223K	0.01%	478
2016 Q2	$9.74M	Sell	1,755,035 -6,009	-0.3%	-$31.6K	0.01%	467
2016 Q1	$7.75M	Buy	1,761,044 +12,932	+0.7%	+$53.2K	0.01%	470
2015 Q4	$10.5M	Buy	1,748,112 +906,153	+108%	+$6.15M	0.01%	480
2015 Q3	$6.58M	Buy	841,959 +165,089	+24%	+$1.28M	0.01%	530
2015 Q2	$4.15M	Sell	676,870 -291,922	-30%	-$2.26M	﹤0.01%	550
2015 Q1	$7.8M	Sell	968,792 -12,400	-1%	-$93.5K	0.01%	501
2014 Q4	$4.96M	Buy	+981,192	New	+$4.85M	﹤0.01%	511

Other funds holding GNMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates's GNMX Position: Q1 2017 in Review

Jennison Associates sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2017, closing a stake of 1,720,838 shares — an estimated $8.91M sold.

Jennison Associates first reported a position in GNMX in Q4 2014 and held it in 9 quarters. The position peaked at $10.5M in Q4 2015. 73 funds tracked by Wall St. Rank hold GNMX as of Q1 2017.

Jennison Associates reported no remaining Aevi Genomic Medicine Inc position as of Q1 2017 after selling out during the quarter.
Jennison Associates sold 1,720,838 Aevi Genomic Medicine Inc shares in Q1 2017, an estimated $8.91M.
Jennison Associates first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 9 quarters.
Jennison Associates's Aevi Genomic Medicine Inc position peaked at $10.5M in Q4 2015.
73 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2017.

Based on Jennison Associates's 13F filing for Q1 2017, filed 28 Apr 2017.